A Phase I/II Radiation Dose Escalation Study With Concurrent Chemotherapy for Patients With Inoperable Stages I to III Non-Small-Cell Lung Cancer: Phase I Results of RTOG 0117

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 2, 2010, Pages 367-372

  Bradley, Jeffrey D ^a   Moughan, Jennifer ^b   Graham, Mary V ^c   Byhardt, Roger ^d   Govindan, Ramaswamy ^a   Fowler, Jack ^e   Purdy, James A ^f   Michalski, Jeff M ^a   Gore, Elizabeth ^d   Choy, Hak ^g  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTOG Headquarters   (United States)

^c Phelps County Regional Medical Center   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Concurrent chemoradiation therapy; Dose escalation; Lung cancer; RTOG

Indexed keywords

CARBOPLATIN; CONCURRENT CHEMORADIATION; CONCURRENT CHEMOTHERAPY; DLTS; DOSE ESCALATION; DOSE LEVELS; DOSE LIMITING TOXICITY; ESOPHAGITIS; FRACTION SIZE; HIGH DOSE; LOW RATES; LUNG CANCER; MAXIMUM TOLERATED DOSE; NON SMALL CELL LUNG CANCER; PACLITAXEL; PHASE I; PHASE II; RADIATION DOSE; RADIATION PNEUMONITIS; RADIATION THERAPY; THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY;

BIOLOGICAL ORGANS; CHEMOTHERAPY; DOSIMETRY; RADIATION; THREE DIMENSIONAL; TOXICITY;

RADIOTHERAPY;

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BACKACHE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; BONE MARROW DISEASE; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOXEMIA; INFECTION; INOPERABLE CANCER; LIVER TOXICITY; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; MYALGIA; NEPHROTOXICITY; NEUROTOXICITY; OUTCOME ASSESSMENT; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION RESPONSE; SKIN TOXICITY; UROGENITAL TRACT DISEASE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL PROTOCOLS; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; ESOPHAGITIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIATION PNEUMONITIS; RADIOTHERAPY, CONFORMAL;

EID: 77951804823     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.029     Document Type: Article

References (13)

1. Perez C.A., Stanley K., Rubin P., et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45 (1980) 2744-2753
2. Bradley J., Graham M.V., Winter K., et al. Toxicity and outcome results of RTOG 9311: A phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 318-328
3. Curran W.J., Scott C., Langer C., et al. Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small-cell lung cancer (NSCLC): Initial report of Radiation Therapy Oncology Group (RTOG) 9410. J Clin Oncol 19 (2000) 1891a
4. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
5. Pierre F., Maurice P., and Gilles R. A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study. ASCO 20 (2001) 312A
6. Zatloukal P., Petruzelka L., Zemanova M., et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46 (2004) 87-98
7. Huber R., Schmidt M., and Flentje M. Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIa/IIIb) (BROCAT-Group). ASCO 22 (2003) 2501A
8. Arbuck S, Ivy S, Setser A. The revised common toxicity criteria. Available at: www.fda.gov/cder/cancer/toxicityframe.htm. Accessed March 28, 2010.
9. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
10. Curran W., Scott C., Langer C., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresectable NSCLC: RTOG 9410. ASCO 22 (2003) 621a
11. Onishi H., Shirato H., Nagata Y., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small-cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2 (2007) S94-S100
12. Schild S., McGinnis W., Graham D., et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63 (2005) S44
13. Socinski M.A., Blackstock A.W., Bogart J.A., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26 (2008) 2457-2463